News

The trial will evaluate the safety, pharmacokinetics and pharmacodynamics of GlycoPEG-GCSF versus Neulasta. The phase I trial is designed to evaluate subcutaneous administration of GlycoPEG-GCSF (G-CSF). “We are

In previous studies, MKC-1 demonstrated broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. Results from the preclinical studies demonstrated that

“Because AN0128 effectively targets inflammation in a topical preparation, it is a promising treatment against atopic dermatitis,” said Dr Karl Beutner, chief medical officer at Anacor. The study

The trial evaluated the effects of mecamylamine taken with citalopram hydrobromide, a treatment combination known as TRIDMAC, in patients who did not respond adequately to citalopram alone. Citalopram

Xcytrin allowed physicians to identify occult brain metastases that are amenable to stereotactic radiosurgery and that were missed with standard MRI contrast agents “These data demonstrate that Xcytrin

The phase I study evaluated patients with advanced solid tumors who had failed prior treatments with a range of anticancer therapies. A total of 43 patients have received

CytoGam is an intravenous immune globulin enriched in antibodies to protect against cytomegalovirus (CMV). It is used to prevent CMV disease associated with transplantation of the kidney, lung,

The milestone payment was triggered by Pharmasset’s successful completion of certain manufacturing activities defined in the hepatitis C virus (HCV) agreement with Roche. This included the development of

High-risk patients include those receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes and hematopoietic stem cell transplant recipients. Invasive fungal infections most often occur in people who